bezafibrate trial summary

No demonstrated result

suggested Coronary event by 16% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amputation	no data
Venous thromboembolism	no data
cardiovascular events	0.94 [0.73 1.21]	p=1.00	0	1568	1	LEADER,
Cardiovascular death	1.04 [0.75 1.46]	p=1.00	0	1568	1	LEADER trial,
stroke (fatal and non fatal)	0.93 [0.67 1.29]	p=1.00	0	3090	1	BIP,
Coronary event	0.84 [0.71 0.99]	p=0.04	0	4903	4	BECAIT,BIP,SENDCAP,LEADER,
Coronary death and non fatal MI	0.91 [0.74 1.11]	p=1.00	0	3090	1	BIP,
Coronary death	1.03 [0.72 1.48]	p=1.00	0	3182	2	BECAIT,BIP,
cardiac death	1.04 [0.84 1.29]	p=1.00	0	4914	4	BECAIT,BIP,SENDCAP,LEADER,
MACE	0.92 [0.79 1.06]	p=1.00	0	3182	2	BECAIT,BIP,
Non fatal MI	0.87 [0.69 1.09]	p=1.00	0	3090	1	BIP,
Revascularization	no data
All cause death	1.05 [0.92 1.20]	p=1.00	0	6482	5	LEADER trial,BECAIT,BIP,SENDCAP,LEADER,
non cardiovascular death	1.03 [0.72 1.46]	p=1.00	0	3182	2	BECAIT,BIP,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	0.57 [0.13 2.56]	p=1.00	0	92	1	BECAIT,
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 4 trials - BECAIT - BIP - SENDCAP - LEADER

No demonstrated result

suggested Coronary event by 16% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	0.94 [0.73 1.21]	p=1.00	0	1568	1	LEADER,
Cardiovascular death	no data
stroke (fatal and non fatal)	0.93 [0.67 1.29]	p=1.00	0	3090	1	BIP,
Coronary event	0.84 [0.71 0.99]	p=0.04	0	4903	4	BECAIT,BIP,SENDCAP,LEADER,
Coronary death and non fatal MI	0.91 [0.74 1.11]	p=1.00	0	3090	1	BIP,
Coronary death	1.03 [0.72 1.48]	p=1.00	0	3182	2	BECAIT,BIP,
cardiac death	1.04 [0.84 1.29]	p=1.00	0	4914	4	BECAIT,BIP,SENDCAP,LEADER,
MACE	0.92 [0.79 1.06]	p=1.00	0	3182	2	BECAIT,BIP,
Non fatal MI	0.87 [0.69 1.09]	p=1.00	0	3090	1	BIP,
All cause death	1.05 [0.90 1.24]	p=1.00	0	4914	4	BECAIT,BIP,SENDCAP,LEADER,
non cardiovascular death	1.03 [0.72 1.46]	p=1.00	0	3182	2	BECAIT,BIP,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	0.57 [0.13 2.56]	p=1.00	0	92	1	BECAIT,
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Diabetic patients : 1 trials - SENDCAP

No demonstrated result

suggested Coronary event by 64% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.36 [0.13 0.97]	p=0.04	0	164	1	SENDCAP,
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	1.02 [0.02 52.27]	p=1.00	0	164	1	SENDCAP,
MACE	no data
Non fatal MI	no data
All cause death	0.34 [0.01 8.51]	p=1.00	0	164	1	SENDCAP,
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with other atherosclerotic localisation: 1 trials - LEADER

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	0.94 [0.73 1.21]	p=1.00	0	1568	1	LEADER,
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.81 [0.60 1.09]	p=1.00	0	1568	1	LEADER,
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	1.05 [0.80 1.38]	p=1.00	0	1568	1	LEADER,
MACE	no data
Non fatal MI	no data
All cause death	1.05 [0.84 1.32]	p=1.00	0	1568	1	LEADER,
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with prior MI or with CHD: 1 trials - SENDCAP

No demonstrated result

suggested Coronary event by 64% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.36 [0.13 0.97]	p=0.04	0	164	1	SENDCAP,
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	1.02 [0.02 52.27]	p=1.00	0	164	1	SENDCAP,
MACE	no data
Non fatal MI	no data
All cause death	0.34 [0.01 8.51]	p=1.00	0	164	1	SENDCAP,
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 1 trials - LEADER trial

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 2 trials - BECAIT - BIP

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	0.93 [0.67 1.29]	p=1.00	0	3090	1	BIP,
Coronary event	0.88 [0.72 1.08]	p=1.00	0	3171	2	BECAIT,BIP,
Coronary death and non fatal MI	0.91 [0.74 1.11]	p=1.00	0	3090	1	BIP,
Coronary death	1.03 [0.72 1.48]	p=1.00	0	3182	2	BECAIT,BIP,
cardiac death	1.01 [0.70 1.45]	p=1.00	0	3182	2	BECAIT,BIP,
MACE	0.92 [0.79 1.06]	p=1.00	0	3182	2	BECAIT,BIP,
Non fatal MI	0.87 [0.69 1.09]	p=1.00	0	3090	1	BIP,
All cause death	1.06 [0.84 1.34]	p=1.00	0	3182	2	BECAIT,BIP,
non cardiovascular death	1.03 [0.72 1.46]	p=1.00	0	3182	2	BECAIT,BIP,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	0.57 [0.13 2.56]	p=1.00	0	92	1	BECAIT,
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Bezafibrate cholesterol lowering intervention